Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 123 entries
Sorted by: Best Match Show Resources per page
N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells.

Redox report : communications in free radical research

Malorni W, Rivabene R, Santini MT, Rainaldi G, Donelli G.
PMID: 27414179
Redox Rep. 1994 Oct;1(1):57-64. doi: 10.1080/13510002.1994.11746957.

It has been hypothesized that reactive oxygen intermediates (ROI) can activate human immunodeficiency virus (HIV) replication and that HIV can trigger programmed cell death (PCD). In this work, we studied PCD in U937 cultured cells chronically infected with HIV...

Cite
Malorni W, Rivabene R, Santini MT, et al. N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells. Redox Rep. 1994;1(1):57-64doi: 10.1080/13510002.1994.11746957.
Malorni, W., Rivabene, R., Santini, M. T., Rainaldi, G., & Donelli, G. (1994). N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells. Redox report : communications in free radical research, 1(1), 57-64. https://doi.org/10.1080/13510002.1994.11746957
Malorni, W, et al. "N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells." Redox report : communications in free radical research vol. 1,1 (1994): 57-64. doi: https://doi.org/10.1080/13510002.1994.11746957
Malorni W, Rivabene R, Santini MT, Rainaldi G, Donelli G. N-acetylcysteine prevents TNF-induced mitochondrial damage, apoptosis and viral particle production in HIV-infected U937 cells. Redox Rep. 1994 Oct;1(1):57-64. doi: 10.1080/13510002.1994.11746957. PMID: 27414179.
Copy Download .nbib Format: NLM
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?.

Cancers

Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A.
PMID: 24670368
Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684.

Circulating tumor cell (CTC) count has prognostic significance in metastatic breast cancer, but the predictive utility of CTCs is uncertain. Molecular studies on CTCs have often been limited by a low number of CTCs isolated from a high background...

Cite
Turner N, Pestrin M, Galardi F, et al. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?. Cancers (Basel). 2014;6(2):684-707doi: 10.3390/cancers6020684.
Turner, N., Pestrin, M., Galardi, F., De Luca, F., Malorni, L., & Di Leo, A. (2014). Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?. Cancers, 6(2), 684-707. https://doi.org/10.3390/cancers6020684
Turner, Natalie, et al. "Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?." Cancers vol. 6,2 (2014): 684-707. doi: https://doi.org/10.3390/cancers6020684
Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?. Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684. PMID: 24670368; PMCID: PMC4074798.
Copy Download .nbib Format: NLM
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Oncotarget

Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L.
PMID: 29662653
Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27.

The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit...

Cite
Bonechi M, Galardi F, Biagioni C, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389-16399doi: 10.18632/oncotarget.24700.
Bonechi, M., Galardi, F., Biagioni, C., De Luca, F., Bergqvist, M., Neumüller, M., Guarducci, C., Boccalini, G., Gabellini, S., Migliaccio, I., Di Leo, A., Pestrin, M., & Malorni, L. (2018). Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget, 9(23), 16389-16399. https://doi.org/10.18632/oncotarget.24700
Bonechi, Martina, et al. "Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy." Oncotarget vol. 9,23 (2018): 16389-16399. doi: https://doi.org/10.18632/oncotarget.24700
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27. PMID: 29662653; PMCID: PMC5893248.
Copy Download .nbib Format: NLM
A multifactorial 'Consensus Signature' by .

NPJ breast cancer

Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A.
PMID: 28721363
NPJ Breast Cancer. 2015 Jun 02;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015.

RESULTS: In the training set, 29 of 147 patients had pCR after anthracycline-based chemotherapy. Various combinations of components were evaluated, with the most powerful anthracycline response predictors being CONCLUSIONS: With further validation,

Cite
Turner N, Forcato M, Nuzzo S, et al. A multifactorial 'Consensus Signature' by . NPJ Breast Cancer. 2015;1:15003doi: 10.1038/npjbcancer.2015.3.
Turner, N., Forcato, M., Nuzzo, S., Malorni, L., Bicciato, S., & Di Leo, A. (2015). A multifactorial 'Consensus Signature' by . NPJ breast cancer, 115003. https://doi.org/10.1038/npjbcancer.2015.3
Turner, Natalie, et al. "A multifactorial 'Consensus Signature' by ." NPJ breast cancer vol. 1 (2015): 15003. doi: https://doi.org/10.1038/npjbcancer.2015.3
Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A. A multifactorial 'Consensus Signature' by . NPJ Breast Cancer. 2015 Jun 02;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015. PMID: 28721363; PMCID: PMC5515202.
Copy Download .nbib Format: NLM
Complete Genome Sequence of .

Genome announcements

Borowiak M, Hammerl JA, Fischer J, Szabo I, Malorny B.
PMID: 28912328
Genome Announc. 2017 Sep 14;5(37). doi: 10.1128/genomeA.00991-17.

In 2015, plasmid-mediated colistin resistance was reported to be caused by a mobilized phosphoethanolamine transferase gene (

Cite
Borowiak M, Hammerl JA, Fischer J, et al. Complete Genome Sequence of . Genome Announc. 2017;5(37)doi: 10.1128/genomeA.00991-17.
Borowiak, M., Hammerl, J. A., Fischer, J., Szabo, I., & Malorny, B. (2017). Complete Genome Sequence of . Genome announcements, 5(37), . https://doi.org/10.1128/genomeA.00991-17
Borowiak, Maria, et al. "Complete Genome Sequence of ." Genome announcements vol. 5,37 (2017). doi: https://doi.org/10.1128/genomeA.00991-17
Borowiak M, Hammerl JA, Fischer J, Szabo I, Malorny B. Complete Genome Sequence of . Genome Announc. 2017 Sep 14;5(37). doi: 10.1128/genomeA.00991-17. PMID: 28912328; PMCID: PMC5597769.
Copy Download .nbib Format: NLM
Antibacterial Activity of Three Extra Virgin Olive Oils of the Campania Region, Southern Italy, Related to Their Polyphenol Content and Composition.

Microorganisms

Nazzaro F, Fratianni F, Cozzolino R, Martignetti A, Malorni L, De Feo V, Cruz AG, d'Acierno A.
PMID: 31491985
Microorganisms. 2019 Sep 05;7(9). doi: 10.3390/microorganisms7090321.

Production of extra virgin olive oil (EVOO) represents an important element for the economy of Southern Italy. Therefore, EVOO is recognized as a food with noticeable biological effects. Our study aimed to evaluate the antimicrobial activity exhibited by the...

Cite
Nazzaro F, Fratianni F, Cozzolino R, et al. Antibacterial Activity of Three Extra Virgin Olive Oils of the Campania Region, Southern Italy, Related to Their Polyphenol Content and Composition. Microorganisms. 2019;7(9)doi: 10.3390/microorganisms7090321.
Nazzaro, F., Fratianni, F., Cozzolino, R., Martignetti, A., Malorni, L., De Feo, V., Cruz, A. G., & d'Acierno, A. (2019). Antibacterial Activity of Three Extra Virgin Olive Oils of the Campania Region, Southern Italy, Related to Their Polyphenol Content and Composition. Microorganisms, 7(9), . https://doi.org/10.3390/microorganisms7090321
Nazzaro, Filomena, et al. "Antibacterial Activity of Three Extra Virgin Olive Oils of the Campania Region, Southern Italy, Related to Their Polyphenol Content and Composition." Microorganisms vol. 7,9 (2019). doi: https://doi.org/10.3390/microorganisms7090321
Nazzaro F, Fratianni F, Cozzolino R, Martignetti A, Malorni L, De Feo V, Cruz AG, d'Acierno A. Antibacterial Activity of Three Extra Virgin Olive Oils of the Campania Region, Southern Italy, Related to Their Polyphenol Content and Composition. Microorganisms. 2019 Sep 05;7(9). doi: 10.3390/microorganisms7090321. PMID: 31491985; PMCID: PMC6780878.
Copy Download .nbib Format: NLM
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN.
PMID: 31603413
Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256.

No abstract available.

Cite
Hotte SJ, Kapoor A, Basappa NS, et al. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Can Urol Assoc J. 2019;13(10):343-354doi: 10.5489/cuaj.6256.
Hotte, S. J., Kapoor, A., Basappa, N. S., Bjarnason, G., Canil, C., Conter, H. J., Czaykowski, P., Graham, J., Gray, S., Heng, D. Y. C., Karakiewicz, P. I., Kollmannsberger, C., Lalani, A. A., North, S. A., Patenaude, F., Soulières, D., Violette, P., Winquist, E., Wood, L. A., Dudani, S., Maloni, R., Reaume, M. N. (2019). Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 13(10), 343-354. https://doi.org/10.5489/cuaj.6256
Hotte, Sebastien J, et al. "Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 13,10 (2019): 343-354. doi: https://doi.org/10.5489/cuaj.6256
Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. PMID: 31603413; PMCID: PMC6788909.
Copy Download .nbib Format: NLM
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.
PMID: 29877179
Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

INTRODUCTION: The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with non-metastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data...

Cite
Karakiewicz PI, Zaffuto E, Kapoor A, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J. 2018;12(6):173-180doi: 10.5489/cuaj.5187.
Karakiewicz, P. I., Zaffuto, E., Kapoor, A., Basappa, N. S., Bjarnason, G. A., Blais, N., Breau, R. H., Canil, C., Drachenberg, D., Hotte, S. J., Jeldres, C., Jewett, M. A. S., Kassouf, W., Kollmannsberger, C., Lavallée, L. T., Maloni, R., Patenaude, F., Pouliot, F., Reaume, M. N., Sabbagh, R., Shayegan, B., So, A., Soulières, D., Tanguay, S., Wood, L., & Bandini, M. (2018). Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(6), 173-180. https://doi.org/10.5489/cuaj.5187
Karakiewicz, Pierre I, et al. "Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,6 (2018): 173-180. doi: https://doi.org/10.5489/cuaj.5187
Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187. PMID: 29877179; PMCID: PMC5994982.
Copy Download .nbib Format: NLM
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R.
PMID: 33536276
Clin Cancer Res. 2021 Sep 01;27(17):4870-4882. doi: 10.1158/1078-0432.CCR-19-4191. Epub 2021 Feb 03.

PURPOSE: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor-positive (EREXPERIMENTAL DESIGN: Parental breast cancer cells and their endocrine-resistant derivatives (EndoR) were used. Derivatives with acquired resistance to palbociclib (PalboR) were generated from parental...

Cite
De Angelis C, Fu X, Cataldo ML, et al. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021;27(17):4870-4882doi: 10.1158/1078-0432.CCR-19-4191.
De Angelis, C., Fu, X., Cataldo, M. L., Nardone, A., Pereira, R., Veeraraghavan, J., Nanda, S., Qin, L., Sethunath, V., Wang, T., Hilsenbeck, S. G., Benelli, M., Migliaccio, I., Guarducci, C., Malorni, L., Litchfield, L. M., Liu, J., Donaldson, J., Selenica, P., Brown, D. N., Weigelt, B., Reis-Filho, J. S., Park, B. H., Hurvitz, S. A., Slamon, D. J., Rimawi, M. F., Jansen, V. M., Jeselsohn, R., Osborne, C. K., & Schiff, R. (2021). Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4870-4882. https://doi.org/10.1158/1078-0432.CCR-19-4191
De Angelis, Carmine, et al. "Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4870-4882. doi: https://doi.org/10.1158/1078-0432.CCR-19-4191
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01;27(17):4870-4882. doi: 10.1158/1078-0432.CCR-19-4191. Epub 2021 Feb 03. PMID: 33536276; PMCID: PMC8628647.
Copy Download .nbib Format: NLM
Outcome of Different Sequencing and Assembly Approaches on the Detection of Plasmids and Localization of Antimicrobial Resistance Genes in Commensal .

Microorganisms

Juraschek K, Borowiak M, Tausch SH, Malorny B, Käsbohrer A, Otani S, Schwarz S, Meemken D, Deneke C, Hammerl JA.
PMID: 33799479
Microorganisms. 2021 Mar 14;9(3). doi: 10.3390/microorganisms9030598.

Antimicrobial resistance (AMR) is a major threat to public health worldwide. Currently, AMR typing changes from phenotypic testing to whole-genome sequence (WGS)-based detection of resistance determinants for a better understanding of the isolate diversity and elements involved in gene...

Cite
Juraschek K, Borowiak M, Tausch SH, et al. Outcome of Different Sequencing and Assembly Approaches on the Detection of Plasmids and Localization of Antimicrobial Resistance Genes in Commensal . Microorganisms. 2021;9(3)doi: 10.3390/microorganisms9030598.
Juraschek, K., Borowiak, M., Tausch, S. H., Malorny, B., Käsbohrer, A., Otani, S., Schwarz, S., Meemken, D., Deneke, C., & Hammerl, J. A. (2021). Outcome of Different Sequencing and Assembly Approaches on the Detection of Plasmids and Localization of Antimicrobial Resistance Genes in Commensal . Microorganisms, 9(3), . https://doi.org/10.3390/microorganisms9030598
Juraschek, Katharina, et al. "Outcome of Different Sequencing and Assembly Approaches on the Detection of Plasmids and Localization of Antimicrobial Resistance Genes in Commensal ." Microorganisms vol. 9,3 (2021). doi: https://doi.org/10.3390/microorganisms9030598
Juraschek K, Borowiak M, Tausch SH, Malorny B, Käsbohrer A, Otani S, Schwarz S, Meemken D, Deneke C, Hammerl JA. Outcome of Different Sequencing and Assembly Approaches on the Detection of Plasmids and Localization of Antimicrobial Resistance Genes in Commensal . Microorganisms. 2021 Mar 14;9(3). doi: 10.3390/microorganisms9030598. PMID: 33799479; PMCID: PMC8000739.
Copy Download .nbib Format: NLM
Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort.

Urology

Lavi A, Breau RH, Mallick R, Kapoor A, Finelli A, So A, Pouliot F, Tanguay S, Lavallée LT, Rendon R, Fairey A, Drachenberg DE, Lattouf JB, Maloni R, Power NE.
PMID: 34129893
Urology. 2021 Nov;157:168-173. doi: 10.1016/j.urology.2021.05.053. Epub 2021 Jun 12.

OBJECTIVE: To characterize proportion of patients receiving adrenalectomy, adrenal involvement prevalence and oncologic outcomes of routine adrenalectomy in contemporary practice. Ipsilateral adrenalectomy was once standard during radical nephrectomy. However, benefit of routine adrenalectomy has been questioned because adrenal involvement...

Cite
Lavi A, Breau RH, Mallick R, et al. Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology. 2021;157:168-173doi: 10.1016/j.urology.2021.05.053.
Lavi, A., Breau, R. H., Mallick, R., Kapoor, A., Finelli, A., So, A., Pouliot, F., Tanguay, S., Lavallée, L. T., Rendon, R., Fairey, A., Drachenberg, D. E., Lattouf, J. B., Maloni, R., & Power, N. E. (2021). Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 157168-173. https://doi.org/10.1016/j.urology.2021.05.053
Lavi, Arnon, et al. "Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort." Urology vol. 157 (2021): 168-173. doi: https://doi.org/10.1016/j.urology.2021.05.053
Lavi A, Breau RH, Mallick R, Kapoor A, Finelli A, So A, Pouliot F, Tanguay S, Lavallée LT, Rendon R, Fairey A, Drachenberg DE, Lattouf JB, Maloni R, Power NE. Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology. 2021 Nov;157:168-173. doi: 10.1016/j.urology.2021.05.053. Epub 2021 Jun 12. PMID: 34129893.
Copy Download .nbib Format: NLM
Photoexcitation dynamics in perylene diimide dimers.

The Journal of chemical physics

Mukazhanova A, Malone W, Negrin-Yuvero H, Fernandez-Alberti S, Tretiak S, Sharifzadeh S.
PMID: 33380092
J Chem Phys. 2020 Dec 28;153(24):244117. doi: 10.1063/5.0031485.

We utilize first-principles theory to investigate photo-induced excited-state dynamics of functionalized perylene diimide. This class of materials is highly suitable for solar energy conversion because of the strong optical absorbance, efficient energy transfer, and chemical tunability. We couple time-dependent...

Cite
Mukazhanova A, Malone W, Negrin-Yuvero H, et al. Photoexcitation dynamics in perylene diimide dimers. J Chem Phys. 2020;153(24):244117doi: 10.1063/5.0031485.
Mukazhanova, A., Malone, W., Negrin-Yuvero, H., Fernandez-Alberti, S., Tretiak, S., & Sharifzadeh, S. (2020). Photoexcitation dynamics in perylene diimide dimers. The Journal of chemical physics, 153(24), 244117. https://doi.org/10.1063/5.0031485
Mukazhanova, Aliya, et al. "Photoexcitation dynamics in perylene diimide dimers." The Journal of chemical physics vol. 153,24 (2020): 244117. doi: https://doi.org/10.1063/5.0031485
Mukazhanova A, Malone W, Negrin-Yuvero H, Fernandez-Alberti S, Tretiak S, Sharifzadeh S. Photoexcitation dynamics in perylene diimide dimers. J Chem Phys. 2020 Dec 28;153(24):244117. doi: 10.1063/5.0031485. PMID: 33380092.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 123 entries